Dr. Sinil Kim
Over to Texas, and Mirna Therapeutics has got a new Vice President of Oncology and Chief Medical Officer in the form of Dr. Sinil Kim.
Kim, most recently a Senior Director at Pfizer and prior to that Director of Clinical Oncology at Bristol-Myers Squibb, will be responsible for directing clinical development of MRX34, Mirna’s first cancer product candidate.
Dr. Paul Lammers, Mirna’s CEO said: “Dr. Kim joins Mirna at an exciting time in our company’s growth, as we have just successfully initiated our MRX34 Phase I trial and are looking forward to further growth and maturation of our proprietary microRNA discovery platform and preclinical pipeline.”